Bibikova Marina, Fan Jianbing
AnchorDx, Inc., 46305 Landing Parkway, Fremont, CA 94538, USA.
Department of Pathology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong 510515, China.
Chin Med J Pulm Crit Care Med. 2023 Oct 20;1(4):200-206. doi: 10.1016/j.pccm.2023.08.005. eCollection 2023 Dec.
Lung cancer is the leading cause of cancer-related mortality worldwide. Early cancer detection plays an important role in improving treatment success and patient prognosis. In the past decade, liquid biopsy became an important tool for cancer diagnosis, as well as for treatment selection and response monitoring. Liquid biopsy is a broad term that defines a non-invasive test done on a sample of blood or other body fluid to look for cancer cells or other analytes that can include DNA, RNA, or other molecules released by tumor cells. Liquid biopsies mainly include circulating tumor DNA, circulating RNA, microRNA, proteins, circulating tumor cells, exosomes, and tumor-educated platelets. This review summarizes the progress and clinical application potential of liquid biopsy for early detection of lung cancer.
肺癌是全球癌症相关死亡的主要原因。早期癌症检测在提高治疗成功率和患者预后方面发挥着重要作用。在过去十年中，液体活检成为癌症诊断以及治疗选择和反应监测的重要工具。液体活检是一个广义术语，指对血液样本或其他体液进行的非侵入性检测，以寻找癌细胞或其他分析物，这些分析物可以包括肿瘤细胞释放的DNA、RNA或其他分子。液体活检主要包括循环肿瘤DNA、循环RNA、微小RNA、蛋白质、循环肿瘤细胞、外泌体和肿瘤诱导血小板。本文综述了液体活检在肺癌早期检测方面的进展及临床应用潜力。
